Jean Jacques Bienaime - Net Worth and Insider Trading

Jean Jacques Bienaime Net Worth

The estimated net worth of Jean Jacques Bienaime is at least $71 Million dollars as of 2024-03-29. Jean Jacques Bienaime is the Director of Biomarin Pharmaceutical Inc and owns about 807,736 shares of Biomarin Pharmaceutical Inc (BMRN) stock worth over $71 Million. Jean Jacques Bienaime is the Director of Incyte Corp and owns about 8,646 shares of Incyte Corp (INCY) stock worth over $492,390. Jean Jacques Bienaime is also the Director of Immunic Inc and owns about 463 shares of Immunic Inc (IMUX) stock worth over $611. Details can be seen in Jean Jacques Bienaime's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jean Jacques Bienaime has not made any transactions after 2024-03-06 and currently still holds the listed stock(s).

Transaction Summary of Jean Jacques Bienaime

To

Jean Jacques Bienaime Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jean Jacques Bienaime owns 6 companies in total, including Incyte Corp () , Biomarin Pharmaceutical Inc () , and Immunic Inc () among others .

Click here to see the complete history of Jean Jacques Bienaime’s form 4 insider trades.

Insider Ownership Summary of Jean Jacques Bienaime

Ticker Comapny Transaction Date Type of Owner
Incyte Corp 2020-11-10 director
Biomarin Pharmaceutical Inc 2024-03-06 director & Chief Executive Officer
Immunic Inc 2018-09-24 director
Portola Pharmaceuticals Inc 2014-05-16 director
NeurogesX Inc 2012-02-07 director
Immunome Inc 2023-11-07 director

Jean Jacques Bienaime Latest Holdings Summary

Jean Jacques Bienaime currently owns a total of 3 stocks. Among these stocks, Jean Jacques Bienaime owns 807,736 shares of Biomarin Pharmaceutical Inc (BMRN) as of March 6, 2024, with a value of $71 Million and a weighting of 99.31%. Jean Jacques Bienaime owns 8,646 shares of Incyte Corp (INCY) as of November 10, 2020, with a value of $492,390 and a weighting of 0.69%. Jean Jacques Bienaime also owns 463 shares of Immunic Inc (IMUX) as of September 24, 2018, with a value of $611 and a weighting of 0%.

Latest Holdings of Jean Jacques Bienaime

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BMRN Biomarin Pharmaceutical Inc 2024-03-06 807,736 87.34 70,547,662
INCY Incyte Corp 2020-11-10 8,646 56.95 492,390
IMUX Immunic Inc 2018-09-24 463 1.32 611

Holding Weightings of Jean Jacques Bienaime


Jean Jacques Bienaime Form 4 Trading Tracker

According to the SEC Form 4 filings, Jean Jacques Bienaime has made a total of 53 transactions in Biomarin Pharmaceutical Inc (BMRN) over the past 5 years, including 0 buys and 53 sells. The most-recent trade in Biomarin Pharmaceutical Inc is the sale of 2,000 shares on March 6, 2024, which brought Jean Jacques Bienaime around $172,220.

According to the SEC Form 4 filings, Jean Jacques Bienaime has made a total of 2 transactions in Incyte Corp (INCY) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Incyte Corp is the sale of 798 shares on November 10, 2020, which brought Jean Jacques Bienaime around $66,234.

According to the SEC Form 4 filings, Jean Jacques Bienaime has made a total of 0 transactions in Immunic Inc (IMUX) over the past 5 years. The most-recent trade in Immunic Inc is the sale of 665 shares on September 24, 2018, which brought Jean Jacques Bienaime around $7,986.

Insider Trading History of Jean Jacques Bienaime

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jean Jacques Bienaime Trading Performance

GuruFocus tracks the stock performance after each of Jean Jacques Bienaime's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jean Jacques Bienaime is 24.97%. GuruFocus also compares Jean Jacques Bienaime's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jean Jacques Bienaime within 3 months outperforms 26 times out of 31 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jean Jacques Bienaime's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jean Jacques Bienaime

Average Relative Return

36.1%

Average relative return per transaction

Outperforming Transactions

77%

24 out of 31 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 9.6 24.97 31.33 36.1 37.84 10.41
Relative Return to S&P 500(%) 8.35 21.7 23.47 20.5 28.43 11.43

Jean Jacques Bienaime Ownership Network

Ownership Network List of Jean Jacques Bienaime

No Data

Ownership Network Relation of Jean Jacques Bienaime


Jean Jacques Bienaime Owned Company Details

What does Incyte Corp do?

Who are the key executives at Incyte Corp?

Jean Jacques Bienaime is the director of Incyte Corp. Other key executives at Incyte Corp include EVP & Chief Medical Officer Steven H Stein , EVP GPS & BD & & Licensing Vijay K Iyengar , and Principal Accounting Officer Thomas Tray .

Incyte Corp () Insider Trades Summary

Over the past 18 months, Jean Jacques Bienaime made no insider transaction in Incyte Corp (). Other recent insider transactions involving Incyte Corp () include a net sale of 57,275 shares made by Steven H Stein , a net sale of 24,981 shares made by Vijay K Iyengar , and a net sale of 2,500 shares made by Thomas Tray .

In summary, during the past 3 months, insiders sold 8,022 shares of Incyte Corp () in total and bought 0 shares, with a net sale of 8,022 shares. During the past 18 months, 155,648 shares of Incyte Corp () were sold and 0 shares were bought by its insiders, resulting in a net sale of 155,648 shares.

Incyte Corp ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Incyte Corp Insider Transactions

No Available Data

Jean Jacques Bienaime Mailing Address

Above is the net worth, insider trading, and ownership report for Jean Jacques Bienaime. You might contact Jean Jacques Bienaime via mailing address: 925 Page Mill Road, Palo Alto Ca 94304.

Discussions on Jean Jacques Bienaime

No discussions yet.